---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-046459"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-04-22T23:59:59+00:00"
generated_at: "2026-06-03T14:11:39.935650+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024

## Summary
- ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.
- Preclinical data selected for oral presentation at ASGCT on May 10, 2024 in Baltimore.
- ADI-270 uses CD27-based targeting and armored design to counteract tumor microenvironment and host T-cell clearance.
- Company confirms IND submission for renal cell carcinoma remains on track for Q2 2024.

## SEC filing metadata
- accession: 0000950170-24-046459
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/0000950170-24-046459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024046459/acet-20240422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-046459
- JSON: https://secwatch.observer/filing/0000950170-24-046459.json
- Plain text: https://secwatch.observer/filing/0000950170-24-046459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.